Zinc supplementation improves ALT level in chronic hepatitis C patients during combination therapy of PEG-interferon .ALPHA.-2b and ribavirin

DOI Web Site 5 References
  • Murakami Y
    Department of Nutritional Science, Faculty of Health and Welfare Science Okayama Prefectural University
  • Koyabu T
    Department of Nutritional Science, Faculty of Health and Welfare Science Okayama Prefectural University
  • Kawashima A
    奈良女子大学大学院人間文化研究科
  • Kakibuchi N
    瀬戸内短期大学食物栄養学科
  • Kawakami T
    Department of Nutritional Science, Faculty of Health and Welfare Science Okayama Prefectural University
  • Takaguchi K
    香川県立中央病院内科
  • Kita K
    喜田医院
  • Okita M
    Department of Nutritional Science, Faculty of Health and Welfare Science Okayama Prefectural University

Bibliographic Information

Other Title
  • Ｃ型慢性肝炎のＰＥＧ‐ＩＦＮ　α‐２ｂ／ｒｉｂａｖｉｒｉｎ併用療法における亜鉛投与のＡＬＴ値改善効果（投与開始８週目までの検討）

Search this article

Abstract

We investigated the effects of zinc supplementation on the clinical observations in chronic hepatitis C patients during PEG-interferon α-2b plus ribavirin (PEG-IFN/R) therapy. Patients were randomly allocated to receive daily 150 mg polaprezinc (Zn group, n=11) or no supplement (control, n=12) in addition to PEG-IFN/R therapy and daily antioxidant vitamin supplementation (300 mg of vitamin E and 600 mg of vitamin C). Ten of 11 patients (91%) in Zn group and 7 of 12 (58%) control patients showed decrease in ALT levels (</=35 U/l) after 8 weeks of therapy. This observation indicates that polaprezinc supplementation may induce antioxidative functions in liver which resulted in improvement of hepatocyte injury during PEG-IFN/R therapy.

Journal

  • Kanzo

    Kanzo 47 (3), 165-, 2006

    The Japan Society of Hepatology

References(5)*help

See more

Keywords

Details

Report a problem

Back to top